Introduction
Executive Summary
Nonalcoholic Steatohepatitis: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Nonalcoholic Steatohepatitis - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• Nonalcoholic Steatohepatitis companies' collaborations, Licensing, Acquisition -Deal Value Trends
Nonalcoholic Steatohepatitis Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Resmetirom: Madrigal Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
ALS-L1023: AngioLab
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
CB4211: CohBar
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
• Comparative Analysis
ALG-055009: Aligos Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..

Inactive Products
• Comparative Analysis
Nonalcoholic Steatohepatitis Key Companies
Nonalcoholic Steatohepatitis Key Products
Nonalcoholic Steatohepatitis- Unmet Needs
Nonalcoholic Steatohepatitis- Market Drivers and Barriers
Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion
Nonalcoholic Steatohepatitis Analyst Views
Nonalcoholic Steatohepatitis Key Companies
Appendix

List of Tables
Table 1 Total Products for Nonalcoholic Steatohepatitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Nonalcoholic Steatohepatitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Key Companies
• Novo Nordisk
• Madrigal Pharmaceuticals
• PharmaKing
• Cirius Therapeutics
• Inventiva Pharma
• Galmed Pharmaceuticals
• AbbVie
• Galectin Therapeutics
• Viking Therapeutics
• Sagimet Biosciences
• Novartis
• Hepion Pharmaceuticals
• Celgene
• Boston Pharmaceuticals
• Bristol-Myers Squibb
• NGM Biopharmaceuticals
• Boehringer Ingelheim
• Axcella Health
• Corcept Therapeutics
• TaiwanJ Pharmaceuticals
• AngioLab
• Oramed
• Can-Fite Biopharma
• Mitsubishi Tanabe Pharma
• MediciNova
• Merck Sharp & Dohme
• Metacrine
• MedImmune
• Lipocine
• Chemomab Therapeutics
• Afimmune
• NorthSea Therapeutics
• Rivus Pharmaceuticals
• HighTide Biopharma
• Hanmi Pharmaceutical
• ENYO Pharma
• Histogen
• Akero Therapeutics
• Enanta Pharmaceuticals
• Gilead Sciences
• Ionis Pharmaceuticals
• Eli Lilly and Company
• Terns Pharmaceuticals
• Sinew Pharma
• Poxel
• CytoDyn
• Future Medicine
• 89bio Ltd.
• HK inno.N
• Arrowhead Pharmaceuticals
• Promethera Biosciences
• Enanta Pharmaceuticals